<SEC-DOCUMENT>0001193125-24-280370.txt : 20241217
<SEC-HEADER>0001193125-24-280370.hdr.sgml : 20241217
<ACCEPTANCE-DATETIME>20241217143958
ACCESSION NUMBER:		0001193125-24-280370
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241217
FILED AS OF DATE:		20241217
DATE AS OF CHANGE:		20241217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241555119

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d809004d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as December&nbsp;17, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d809004dex991.htm">Immutep announces initial safety data from IMP761 phase 1 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December 17, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d809004dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g809004g30z01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Initial Safety Data from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">First-in-Human</FONT></FONT> Phase I Trial Evaluating IMP761 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Favourable safety profile for world&#146;s first <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist, IMP761,
with no treatment related adverse events to date </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional safety data and assessment of PK/PD relationships to follow in first half of CY2025
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IMP761&nbsp;is designed to enhance the &#147;brake&#148; function of
<FONT STYLE="white-space:nowrap">LAG-3</FONT> on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 17</B><B></B><B>&nbsp;December 2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces favourable initial safety data from the placebo-controlled,
double-blind <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase I study evaluating IMP761. Through the first three of five single ascending dose cohorts in healthy participants, there have been no
treatment related adverse events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel, CSO of Immutep, said: &#147;We are very encouraged by the safety data
generated to date for IMP761, the world&#146;s first <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody, in this Phase I setting. Derisking this promising asset in this
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> study in healthy subjects assessing its safety and immunosuppressive efficacy on an antigen-specific <FONT STYLE="white-space:nowrap">T-cell</FONT>
mediated intra-dermal reaction is an important step for this exciting program in autoimmune diseases. Given that IMP761 is potentially addressing the root cause of many different autoimmune diseases, we are eager to see this study generating more
data.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trial in up to 49 participants is being conducted by the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands. In addition to
the safety analysis, CHDR is implementing its keyhole limpet haemocyanin (KLH) challenge model to evaluate IMP761&#146;s pharmacological activity. Additional safety data and assessment of pharmacokinetic/pharmacodynamic (PK/PD) relationships to
follow in the first half of CY2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">LAG-3</FONT> (lymphocyte-activation
<FONT STYLE="white-space:nowrap">gene-3)</FONT> immune checkpoint has been identified as a promising target for an agonist antibody to treat rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, among potentially many other autoimmune
diseases.<SUP STYLE="font-size:75%; vertical-align:top">1,2,3</SUP>&nbsp;This <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> agonist <FONT STYLE="white-space:nowrap">LAG-3</FONT> antibody is designed
to restore balance to the immune system by enhancing the &#147;brake&#148; function of <FONT STYLE="white-space:nowrap">LAG-3</FONT> to silence dysregulated self-antigen-specific memory T cells that cause many autoimmune diseases. In preclinical
studies, IMP761 has led to a large decrease in inflammatory cytokines and demonstrated its effectiveness in suppressing antigen-specific T cell&#150;mediated immune responses.<SUP STYLE="font-size:75%; vertical-align:top">4,5</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on the trial, please visit clinicaltrials.gov (NCT06637865). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP761 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761, a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive lymphocyte-activation <FONT STYLE="white-space:nowrap">gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3)</FONT> agonist antibody, has the potential to address the root
cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at disease sites and restoring balance to the immune system. As published in the&nbsp;<U>Journal of Immunology</U>, encouraging <FONT
STYLE="white-space:nowrap">pre-clinical</FONT><I>&nbsp;in vivo</I><I></I>&nbsp;and<I></I><I>&nbsp;in vitro</I>&nbsp;studies show IMP761 inhibits peptide-</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g809004g30z01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
induced T cell proliferation, activation of human primary T cells, and an antigen-specific delayed-type hypersensitivity (DTH) reaction. Additional preclinical data in oligoarticular juvenile
idiopathic arthritis <FONT STYLE="white-space:nowrap">(o-JIA)</FONT> published in&nbsp;<U>Pediatric Research</U>&nbsp;details how IMP761 led to a decrease in a broad spectrum of effector cytokines in just 48&#8201;hours. This study also showed
children with <FONT STYLE="white-space:nowrap">o-JIA</FONT> have a skewed <FONT STYLE="white-space:nowrap">LAG-3</FONT> metabolism and suggested they can benefit from agonistic <FONT STYLE="white-space:nowrap">LAG-3</FONT> activity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Pedersen, J.M., Hansen, A.S., Skej&oslash;, C. et al. Lymphocyte activation gene 3 is increased and affects
cytokine production in rheumatoid arthritis. Arthritis Res Ther 25, 97 (2023). <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1186/s13075-023-03073-z</FONT></FONT> </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Jones BE, Maerz MD et al. Fewer <FONT STYLE="white-space:nowrap">LAG-3+</FONT> T Cells in
Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes. J Immunol. 2022 Feb <FONT STYLE="white-space:nowrap">1;208(3):594-602.</FONT> doi: 10.4049/jimmunol.2100850. Epub 2022 Jan 12. PMID: 35022272; PMCID: PMC8820445. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Zhou X, Gu Y et al. From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy
for autoimmune diseases. Inflamm Res. 2023 Jun;72(6):1215-1235. doi: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10.1007/s00011-023-01742-y.</FONT></FONT></FONT> Epub 2023 Jun 14. PMID:
37314518. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>4.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Mathieu Angin, Chrystelle Brignone, Fr&eacute;d&eacute;ric Triebel; A
<FONT STYLE="white-space:nowrap">LAG-3&#150;Specific</FONT> Agonist Antibody for the Treatment of T Cell&#150;Induced Autoimmune Diseases. J Immunol 15&nbsp;February 2020; 204 (4): 810&#150;818.&nbsp;https://doi.org/10.4049/jimmunol.1900823
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>5.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Sag, E., Demir, S., Aspari, M. et al. Juvenile idiopathic arthritis: lymphocyte activation <FONT
STYLE="white-space:nowrap">gene-3</FONT> is a central immune receptor in children with oligoarticular subtypes. Pediatr Res 90, 744&#150;751
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(2021).&nbsp;https://doi.org/10.1038/s41390-021-01588-2</FONT></FONT></FONT> </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Sodali&nbsp;&amp; Co </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>catherine.strong@sodali.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g809004g30z01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g809004g30z01.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MV&AQQO>RE!(V% &30!H(X= Z-N4@$$=Q0 ^@ H * "@ H * "@ H * "@ H
M#TH :3CKQ^- #J "@ H * "@ H J:E&\NG7$4>=[1L%QZXJ9(F:]T\^T.^,>
MHVT5UE[521L;D1GUK%:,\VE.TM3=\0:GI]]:"T@N8_/)&)!P%QZFJDSIJS7*
M5_!$;+?7I#!D"@;E^Z3GM51,\*FFV=LO2M#OO<6@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MHO8#U+2;]-4TNWO8QA9D#8]#W%%QEW'M19,6@8H&**!!0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M<:H/^)1>_P#7%_Y&MY?"=]5_NWZ'.^!.(;SZI_(UG2V.7"NZ.3C/D_$DESM
MOR<GW8ULSN9ZI?\ &G7/_7-OY&D(\S^&W_(R3?\ 7HW_ *&M $7Q"&/%'/'[
ME: /5("#!&>HP.?PH X/XFK(8=,8 [,N#['Y2/Y&@#,T+P[KFHZ5#<V.L^3
M2Q6,3.-AS[4 7+CP#KUWM^T:M%-MSM\R1VQGKU% &EXCL9--^'@LYF#O%L5F
M'0_-]* -#P#QX1MO]Y__ $(T 9/Q,DC6RT]./,,C,!Z# S0!L^!%9?"-IN!&
M2Y&?3<<4 =)0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'1]0L=:FN;NSF@A,#*#(NW)+ ]#SVH N>//#5UJ,L6H641ED1-DD:\DCKP*
M,FWUWQBMK':16,^4 &6MSNQ[DT =OKFBIK^B?9IODGP'1C_ ^* //[6+Q7X5
MF>*WMIFC8Y.R(RQM[\<B@#1C\0>,[V:-4L98TW#<5MB!C//+4 =#X\S_ ,(E
M/D8.^//_ 'T* .*T35/$^FZ9$+"UDGLFSMQ"74'//(&10 Y='\1>*]4634(I
M8DZ-)+&8PJ_[(- 'J=E:1V-G%:PC$<2A10!8H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJ@],F@"1KR",R;GQY6-P.1UZ?6@#!\>'/A*?G^-#_P"/4 +X!_Y%&V_WG_\
M0C0!TU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@!*8:A0&H4!J% :A0&H4!J% :A0&H4
M!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4
M!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4
M!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4
M!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4
M!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H<
M4!J% :G(#QU$<#[#)TS]X5ASG%]:0[_A.(O^?*3_ +Z%'.'UI!_PG$7_ #Y2
M?]]"CG#ZT@_X3B+_ )\I/^^A1SA]:0?\)Q%_SY2?]]"CG#ZT@_X3B+_GRD_[
MZ%'.'UI!_P )Q%_SY2?]]"CG#ZT@_P"$XB_Y\I/^^A1SA]:0?\)Q%_SY2?\
M?0HYP^M(/^$XB_Y\I/\ OH4<X?6D'_"<1?\ /E)_WT*.</K2#_A.(O\ GRD_
M[Z%'.'UI!_PG$7_/E)_WT*.</K2#_A.(O^?*3_OH4<X?6D'_  G$7_/E)_WT
M*.</K2#_ (3B+_GRD_[Z%'.'UI!_PG$7_/E)_P!]"CG#ZT@_X3B+_GRD_P"^
MA1SA]:0?\)Q%_P ^4G_?0HYP^M(/^$XB_P"?*3_OH4<X?6D'_"<1?\^4G_?0
MHYP^M(/^$XB_Y\I/^^A1SA]:0?\ "<1?\^4G_?0HYP^M(/\ A.(O^?*3_OH4
M<X?6D'_"<1?\^4G_ 'T*.</K2#_A.(O^?*3_ +Z%'.'UI!_PG$7_ #Y2?]]"
MCG#ZT@_X3B+_ )\I/^^A1SA]:0?\)Q%_SY2?]]"CG#ZT@_X3B+_GRD_[Z%'.
M'UI!_P )Q%_SY2?]]"CG#ZT@_P"$XB_Y\I/^^A1SA]:0?\)Q%_SY2?\ ?0HY
MP^M(/^$XB_Y\I/\ OH4<X?6D'_"<1?\ /E)_WT*.</K2#_A.(O\ GRD_[Z%'
M.'UI!_PG$7_/E)_WT*.</K2#_A.(O^?*3_OH4<X?6D'_  G$7_/E)_WT*.</
MK2#_ (3B+_GRD_[Z%'.'UI!_PG$7_/E)_P!]"CG#ZT@_X3B+_GRD_P"^A1SA
M]:0?\)Q%_P ^4G_?0HYP^M(/^$XB_P"?*3_OH4<X?6D'_"<1?\^4G_?0HYP^
MM(/^$XB_Y\I/^^A1SA]:0?\ "<1?\^4G_?0HYP^M(/\ A.(O^?*3_OH4<X?6
MD'_"<1?\^4G_ 'T*.</K2#_A.(O^?*3_ +Z%'.'UI!_PG$7_ #Y2?]]"CG#Z
MT@_X3B+_ )\I/^^A1SA]:0?\)Q%_SY2?]]"CG#ZT@_X3B+_GRD_[Z%'.'UI!
M_P )Q%_SY2?]]"CG#ZT@_P"$XB_Y\I/^^A1SA]:0?\)Q%_SY2?\ ?0HYP^M(
M/^$XB_Y\I/\ OH4<X?6D'_"<1?\ /E)_WT*.</K2#_A.(O\ GRD_[Z%'.'UI
M!_PG$7_/E)_WT*.</K2#_A.(O^?*3_OH4<X?6D'_  G$7_/E)_WT*.</K2#_
M (3B+_GRD_[Z%'.'UI!_PG$7_/E)_P!]"CG#ZT@_X3B+_GRD_P"^A1SA]:0?
M\)Q%_P ^4G_?0HYP^M(/^$XB_P"?*3_OH4<X?6D'_"<1?\^4G_?0HYP^M(/^
M$XB_Y\I/^^A1SA]:0?\ "<1?\^4G_?0HYP^M(/\ A.(O^?*3_OH4<X?6D'_"
M<1?\^4G_ 'T*.</K2#_A.(O^?*3_ +Z%'.'UI!_PG$7_ #Y2?]]"CG#ZT@_X
M3B+_ )\I/^^A1SA]:0?\)Q%_SY2?]]"CG#ZT@_X3B+_GRD_[Z%'.'UI!_P )
MQ%_SY2?]]"CG#ZT@_P"$XB_Y\I/^^A1SA]:0?\)Q%_SY2?\ ?0HYP^M(/^$X
MB_Y\I/\ OH4<X?6D'_"<1?\ /E)_WT*.</K2#_A.(O\ GRD_[Z%'.'UI!_PG
M$7_/E)_WT*.</K2#_A.(O^?*3_OH4<X?6D'_  G$7_/E)_WT*.</K2#_ (3B
M+_GRD_[Z%'.'UI!_PG$7_/E)_P!]"CG#ZT@_X3B+_GRD_P"^A1SA]:0?\)Q%
M_P ^4G_?0HYP^M(/^$XB_P"?*3_OH4<X?6D'_"<1?\^4G_?0HYP^M(/^$XB_
MY\I/^^A1SA]:0?\ "<1?\^4G_?0HYP^M(/\ A.(O^?*3_OH4<X?6D'_"<1?\
M^4G_ 'T*.</K2#_A.(O^?*3_ +Z%'.'UI"?\)Q%G'V*3_OH4<X?6D:=IKXNK
M5)Q;LH?G!8>M/G#ZTCD&L;94R(NWJ:S,.5=B+[)!_P \A0'*NP?9(/\ GD*
MY5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4
M!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_
MYY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!
M_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP
M?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD*
MY5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4
M!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_
MYY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!
M_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP
M?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD*
MY5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4
M!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_
MYY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!
M_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP
M?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD*
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9/8D4!RKL=)IMM$NGPJJX 'J?6F'*NQ__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
